Vetoquinol - Universal Registration Document - 2021

CONSOLIDATED FINANCIAL STATEMENTS Notes to the consolidated financial statements 86 Vetoquinol Universal Registration Document 2020 Financial report 6 Analysis of net deferred taxes by type: €000 Dec 31, 2020 Dec 31, 2019 Intangible assets (5,670) (4,055) Component-based approach (net) 254 290 Other temporary differences (net) 1,665 1,699 Internal margin on inventories 4,156 2,680 Restatement of finance leases (36) (36) Employee benefits 2,159 2,005 Tax losses carried forward 609 287 Regulated provisions (1,826) (1,659) Other (net)* 68 18 TOTAL 1,379 1,230 Of which: Deferred tax assets 9,810 9,005 Deferred tax liabilities (8,431) (7,775) * Including exchange differences 6.5.19 Earnings per share 6.5.18.1 Basic earnings per share Basic earnings per share is calculated by dividing net income attributable to holders of common shares (net income Group share) by the weighted average number of common shares outstanding during the year, adjusted for the number of treasury shares held. €000 Dec 31, 2020 Dec 31, 2019 Net income attributable to holders of common shares (€000) 19,221 28,589 Weighted average number of common shares 11,881,902 11,881,902 Treasury shares at end of period (direct holding) (53,240) (47,994) Treasury shares at end of period (liquidity contract) (2,505) (2,084) Adjusted weighted average number of shares outstanding over the period 11,826,157 11,831,824 BASIC EARNINGS PER SHARE (€) 1.63 2.42